Browsing Tag
Clarity Pharmaceuticals
3 posts
Clarity Pharmaceuticals begins Phase II SECuRE trial with first patient dosed using 67Cu-SAR-bisPSMA and enzalutamide
Clarity Pharmaceuticals starts Phase II of SECuRE trial for prostate cancer, combining 67Cu-SAR-bisPSMA with enzalutamide in first treated patient.
Clarity Pharmaceuticals bags FDA fast track designation for prostate cancer candidate 67Cu-SAR-bisPSMA
Clarity Pharmaceuticals has achieved a major regulatory milestone with the United States Food and Drug Administration (FDA) granting…
Clarity Pharmaceuticals advances in SECuRE trial with promising prostate cancer treatment results
Clarity Pharmaceuticals (ASX: CU6), a clinical stage radiopharmaceutical company, announced significant progress in the SECuRE trial, marking a…